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Abstract
Hepatitis C virus (HCV) continues to be a public health 
problem worldwide. The development of drugs that 
target virus proteins such as NS5B, aims to provide 
more effective treatment in the future. These direct-
acting antivirals (DAAs) have demonstrated potent in 
vitro and in vivo effect; however, mutations have been 
described in HCV NS5B associated with resistance to 
DAA. Detecting mutations that are resistant to DAAs is 
important to prevent potential treatment failures. In this 
work, we developed a software to analyze mutations 
that are resistant to DAAs in NS5B gene of HCV. For 
this, we used the NS5B gene sequence isolate Con1 
genotype 1b HCV, based on the main positions muta-
tions associated with resistance to DAAs in vitro and 
in vivo described in the literature. The software algo-
rithm allows computer analysis of possible changes 
in nucleotide and amino acid positions associated 
with resistance mutations to DAAs in NS5B of HCV.
Keywords: antivirals, computational analysis, hepatitis 
C virus, NS5B.
Resumen 
El virus de la hepatitis C (VHC) continúa siendo un 
problema de salud pública en todo el mundo. El desa-
rrollo de medicamentos que se dirigen a las proteínas 
del virus como NS5B, tiene como objetivo propor-
cionar un tratamiento más eficaz en el futuro. Estos 
antivirales de acción directa (DAA) han demostrado 
un potente efecto in vitro e in vivo; sin embargo, se 
han descrito mutaciones en la NS5B del VHC asociada 
a la resistencia a DAA. La detección de mutaciones 
que son resistentes a DAA es importante para evitar 
posibles fallas de tratamiento. En este trabajo, desarro-
llamos un software para analizar mutaciones que son 
resistentes a los DAA en el gen NS5B del VHC. Para 
esto, utilizamos la secuencia del gen NS5B aislada 
Con1 genotipo 1b HCV, con base en las principales 
posiciones asociadas con la resistencia a DAA in 
vitro e in vivo descritas en la literatura. El algoritmo 
del software permite el análisis computacional de 
posibles cambios en las posiciones de nucleótidos y 
aminoácidos asociadas con mutaciones de resistencia 
a DAA en NS5B de HCV.
Palabras clave: antivirales, análisis computacional, 
virus de la hepatitis C, NS5B.
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1. Introduction
The hepatitis C virus (HCV) was molecularly charac-
terized in 1989 [1], following numerous investiga-
tions to identify the genome of the non-A and non-B 
(NANB) hepatitis viruses, recognized as the major 
cause of hepatitis C and a major cause of chronic 
hepatitis. It is estimated that 200 million patients 
worldwide are infected with HCV and approximately 
130-150 million (3% of the world’s population) live 
with chronic hepatitis C. About 3-4 million people are 
infected every year, and more than 350,000 people 
die every year from hepatitis C-related diseases [2].
Until very recently, the treatment used for HCV was 
a combination of two non-specific drugs immune 
modulators pegylated interferon-α (peg-IFN-α) and 
ribavirin (rBV) [3], as the effectiveness is unsatisfac-
tory in approximately 50-60% of infected patients, 
and relapse occurs in 5-20% of patients treated. 
The long duration of treatment makes it difficult for 
patients to tolerate the associated side effects such 
as asthenia, myalgia, fever, headache, anorexia, ane-
mia, skin rashes, fatigue, etc. [4], and most patients 
have to cease treatment due to these side effects. 
These limitations brought about the development of 
new and more effective drugs with fewer side ef-
fects that target virus proteins, called “Direct-acting 
antivirals” (DAAs)[5].
Each step in the HCV life cycle is a potential target 
for inhibiting molecules. Among different viral en-
zymes, the most research has been done into pro-
tease NS3, NS5A and NS5B rNA-dependent rNA 
polymerase [6]. NS3/4A protease is necessary for 
cutting polyprotein, and is required for the formation 
of the replicase complex. Protease inhibitors prevent 
this process and block the formation of the replicase 
complex. Furthermore, the virus needs NS5B poly-
merase to replicate as it joins the replicase complex 
to the host cell and amplifies its genetic material. 
Therefore the inhibition of NS5B polymerase stops 
the replication process [7]. The first inhibitory agents 
of these two virus enzymes quickly demonstrated 
high antiviral efficacy in vitro and in vivo. Currently, 
there are more than 30 DAAs, some of which are 
in the advanced stages of clinical development and 
others, which have already been approved for use. 
However, mutations resistant to new DAAs, both in 
vitro and in vivo have been observed [8, 9]. Cur-
rent data indicate that viral strains with mutations 
resistant to NS3 protease inhibitors, NS5A inhibitors, 
and NS5B polymerase inhibitors are circulating in 
7.7%, 16.2% and 22.5%, of infected patients [10]. It 
is likely that these viral strains contribute to the de-
velopment of a resistance to DAAs during the initial 
weeks of monotherapy treatment [11]. resistance 
can also develop quickly when the combination 
of two DAAs is used in treatment. Similar to the 
treatment of HIV, a combination of agents may be 
required to optimize viral suppression and prevent 
the development of resistance [12].
The detection of viral strains resistant to new AADs 
is a factor that should be considered at the begin-
ning of and during the treatment of infected patients 
to prevent future errors [13].
Advances in technology, particularly advances in 
bioinformatics, can certainly contribute to the de-
velopment of invaluable computational methods for 
managing treatment of HCV-infected patients. The 
aim of this paper was to develop an online infor-
mation system which included the profiles of viral 
strains resistant to DAAs for the HCV NS5B gene.
2. Materials and methods
HCV isolate Con1 was used as a reference sequence 
to develop the online information system. This infor-
mation was extracted from the GenBank database 
(code AJ238799) (www.ncbi.nlm.nih.gov/genbank/).
This isolate was chosen as a reference sequence be-
cause it is the prototype used to build the replicon 
used in the development of most new DAAs. The 
nucleotide sequence of the NS5B gene was selected 
in plain text format (1,773 bp) for the design of the 
computational analysis of mutations. The positions 
of mutations associated with resistance DAAs in vitro 
and in vivo considered for algorithm development, 
are described in the literature for the HCV NS5B 
gene genotype1 subtipo1b[14-16].
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The algorithm was designed so that the nucleotide 
sequences of the NS5B gene being analyzed are 
compared with the reference sequence to show 
nucleotide and amino acid changes at positions re-
lated to resistance mutations known to occur in the 
HCV NS5B gene. The resultant algorithm is part of an 
information system, which was developed using free 
software tools to provide an easy to use application 
for users to calculate results immediately without 
the need to download and install components or 
additional applications. This software is available 
on the web site: http://bma.itiud.org
3. Results
The information system provides an explanation of 
the mutation positions, antivirals, and a bibliography 
of resistance mutations AADs (Figure 1).
The algorithm was developed for the computational 
analysis of the positions associated with mutations 
described in the literature as causing resistance to 
DAAs which occur in the NS5B gene. The algo-
rithm can incorporate (n) the numbers of nucleo-
tide sequences which it then compares with the 
reference sequence of isolate Con1 genotype 1b, of 
HCV. It then calculates the number and the types of 
nucleotide and amino acid changes and highlights 
the amino acid changes that have occurred due to 
nucleotide changes.
In a simulation test to analyze mutations at positions 
associated with mutations described in the litera-
ture as causing resistance: 159, 282, 316, 320, 414, 
419, 423, 426, 448, 482, 494, 554, 556, 559, the 
online information system analyzed the nucleotide 
sequence problem of the NS5B gene of HCV from a 
patient quickly and easily. When executing the algo-
rithm with the nucleotide sequence, the frequency 
and the number of nucleotide changes in positions of 
interest are detailed for better interpretation: TGC → 
AAC = 1, CTT → CTC = 1, ATG → TTA = 1 y AGC → 
Figure 1. Mutations positions, antivirals and references of the HCV NS5B gene.
Source: Own. 
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GGC = 1. The online information system highlights 
in red the amino acid changes found in positions 
analyzed 316: TGC (C) → AAC (N), 426: ATG (M) 
→ TTA (L) y 556: AGC (S) → GGC (G) (Figure 2).
A “force-directed” graph that identifies mutations 
of each patient sequence through node grouping, 
which corresponds to each analyzed sequence 
(Figure 3).
4. Discussion
HCV infection is a major public health problem. It 
is estimated that 200 million people worldwide are 
currently infected. The conventional treatment used 
for HCV based on the combination of two nonspe-
cific drugs peg-IFN-α/rBV, is a long-term treatment, 
associated with numerous side effects and effective 
Figure 2. result of the simulation performed in the mutation analysis for HCV NS5B gene.
Source: Own.
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in approximately 50% of patients, with little success 
in patients infected with genotype 1. For this reason, 
new DAAs have been developed, some of which are 
specifically designed to inhibit NS5B polymerase 
which is essential for virus replication [17-19].
The use of antivirals that specifically target HCV pro-
teins means it is possible to select preexisting resistant 
strains by selective pressure. Antiviral resistance is as 
a result of amino acid changes that produce confor-
mational changes that interfere with the interaction 
between the drug and the target. The existence of re-
sistant virus among in the infected population can 
be positively selected during therapy and result in a 
treatment failure [19]. Theoretically, before undergo-
ing treatment, all patients infected with HCV have a 
heterogeneous population of genomes which may in-
clude DAA-resistant strains. Hence, the importance of 
identifying and analyzing the existence of such substitu-
tions in the infected people to avoid treatment failure.
Most published studies have evaluated the mu-
tations that confer resistance to new DAAs in 
HCV genotype 1, because most of antivirals have 
been developed using enzyme assays based on 
polymerases of this genotype, especially German 
isolated Con1. Therefore the nucleotide sequence 
of the NS5B gene isolate Con1 genotype 1b HCV, 
has served as a reference to design the online 
algorithm information system for computational 
analysis of the positions associated with muta-
tions of clinical significance described in the 
literature as causing resistance to DAAs active 
in the NS5B gene.
Computational detection of mutations associated 
with resistance to new DAAs would be an impor-
tant software tool for sequence analysis, because it 
is freely available software and it is not the same as 
other free software such as Bioedit, or MEGA. Al-
though these other systems allow the researcher to 
Figure 3. Force Directed Graph visualization. result of the simulation performed in the mutation analysis for HCV NS5B gene.
Source: Own.
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perform analyses for the identification of mutations, 
our software design provides detailed information 
on positions of the mutations, amino acid changes 
that are of clinical interest, antivirals and literature 
on mutations resistant to DAAs.
Using the information system for the analysis of mu-
tations resistant to DAAs designed and developed 
in this paper, a clinician would have additional in-
formation that would allow him/her to choose the 
correct DAAs for HCV treatment. However, it is 
important to mention that the NS5B nucleotide se-
quence of the gene obtained by the Sanger sequenc-
ing method is required to use the analysis algorithm 
information system. 
It would be important to carry out the analysis of 
mutations resistant to DAAs before the treatment, 
during the first days of treatment and at the end of 
treatment in order to control the possible emer-
gence of viral strains resistant to DAAs in the short 
and long term. Thus, by using antiviral tracking, it 
is possible to prevent treatment failures involving 
new DAAs.
5. Conclusions
The online information system allows quick, easy 
and effective computational analysis of mutations, 
providing a detailed view of changes in nucleotides 
and amino acids and supplying the clinician with 
additional information necessary to adjust the treat-
ment of the HCV infection with DAAs.
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